MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness

Area of Science:

• Immunology
• Transplantation Medicine
• Genetics

Background:

• Graft versus host disease (GVHD) affects about 50% of allogeneic hematopoietic stem cell transplantation (HSCT) recipients.
• Glucocorticoids (GC) are the primary treatment, but steroid-refractory (SR) GVHD has a poor prognosis.
• Macrophage migration inhibitory factor (MIF) plays a role in immune reactions and can counteract GC's anti-inflammatory effects.

Purpose of the Study:

• To investigate the association between functional polymorphisms in the MIF gene and the development of acute GVHD (aGVHD) after allogeneic HSCT.
• To determine if MIF gene polymorphisms and serum levels can predict steroid-refractory aGVHD.

Main Methods:

• Analyzed two functional polymorphisms in the MIF gene (-794 CATT5-8 and -173 G/C) in 86 allogeneic HSCT patients.
• Measured MIF serum levels at various time points before and after HSCT.

Main Results:

• Increased frequencies of high-expression MIF genotypes (-794 CATT7) were observed in patients with grade III-IV aGVHD compared to those without or with grade II aGVHD.
• MIF-794 CATT7 and -173 C genotypes were significantly associated with steroid-refractory aGVHD.
• Elevated circulating MIF levels were found to precede the onset of severe aGVHD.

Conclusions:

• Genetically determined high MIF expression is associated with the worsening of aGVHD.
• MIF genotypes may serve as a predictive biomarker for identifying patients with steroid-refractory disease, potentially improving treatment strategies.